English
繁體中文
ALL
2022
2021
2020~2015
Nov 19, 2021
SyneuRx Announces Oral COVID-19 Twindemic Antiviral Drug Candidate Pentarlandir Has Entered Final Portion of FDA Phase II Testing
Jun 23, 2021
SyneuRx Announces Closing of Public Offering
Jun 08, 2021
Taiwan FDA Approves SyneuRx’s IND Application for COVID-19 Clinical Trial
Jun 03, 2021
SyneuRx Files an IND Application for COVID-19 Clinical Trial in Taiwan SyneuRx Initiates Clinical Trial SNB01 Pentarlandir® For Covid-19
Apr 27, 2021
SyneuRx Initiates Clinical Trial SNB01 Pentarlandir® For Covid-19
Mar 26, 2021
US FDA Approves SyneuRx’s IND Application for a Phase II Clinical Trial for Adult Patients with Treatment-Resistant Depression and Suicidal Symptoms
Mar 08, 2021
TFDA Approves SyneuRx's Schizophrenia Trials in Taiwan as part of its Global Schizophrenia Trials
Feb 26, 2021
Ω-NaBen, the Ultimate and Supreme Sodium Benzoate
Feb 04, 2021
US FDA Approves SyneuRx’s IND Application for a First-in-Human, Proof of Principle Clinical Trial for Patients with Early and Mild COVID-19
